Synvisc is one of several* hyaluronate derivatives used as viscosupplements. Chemically, it is a long-chain polymer of repeating disaccharide -[glucuronate-acetylglucosamine]- units. It was first isolated from the vitreous humour of the eye and is now extracted from rooster combs.

*(Hyalgan, Synvisc, Gel-One, Euflexxa, Orthovisc, Supartz, etc)

**Authorization:** Osteoarthritis of the knee in patients who have failed nonpharmacologic treatment and simple analgesics or nonsteroidal anti-inflammatory drugs

**Dosing:** 16mg (2mL, intra-articular) once weekly for three weeks

**PRECAUTIONS:** Inject directly into the knee joint; do not inject extra-articularly or into the synovial capsule or tissues. Do not use disinfectants containing quaternary ammonium salts for skin cleansing prior to injection (may precipitate the HA). Remove synovial fluid or effusion, if present, prior to injection. If used for bilateral treatment, use a separate syringe for each knee. Refer to manufacturer’s labeling for additional instructions on injection technique. Avoid if skin or joint infection is suspected. Watch for subsequent signs of infection. Should be administered by a specialist competent in the use of this medicament.

**DRUG INTERACTIONS:** none reported
REFERENCES


Revision History:
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/Archived: 1/1/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates/Date Unarchived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD;</td>
<td>Annual review</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Robert Sterling, MD</td>
<td></td>
</tr>
<tr>
<td>1/1/18</td>
<td>No</td>
<td>Catherine Sanders, MD;</td>
<td>Archived – excluded from the Formulary effective 1/1/18</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Robert Sterling, MD</td>
<td></td>
</tr>
<tr>
<td>1/22/19</td>
<td>Yes</td>
<td>Catherine Sanders, MD;</td>
<td>Unarchived – Formulary Exclusion –</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Robert Sterling, MD</td>
<td>For Exception Review Use Only</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Annual Review</td>
</tr>
</tbody>
</table>